An alternative approach based on the CRISPR-based double knockout (CDKO) system was applied in the CML K-562 cell line to discover novel synergistic drug combinations, highlighting that the dual inhibition of BCL2L1 and MCL1 may be an effective way to combat resistance in CML [87]. The gene discussed is BCL2L1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.